For patients with heart failure (HF), a greater focus on medication management may be needed in order to mitigate HF exacerbations caused by certain ...

“Beneficial pediatric obesity treatment response yielded enduring health benefits, markedly lowering future morbidity and mortality risks in young adulthood,” the authors write. Several authors ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

HealthDay News — Heart disease continues to be a leading cause of death, according to a report from the American Heart Association published online January 27 in Circulation.

Dapagliflozin plus calorie restriction beneficial for patients with overweight or obesity and type 2 diabetes.

The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show ...

HealthDay News — Stimulant dispensing to children aged 5 to 17 years decreased after the start of the COVID-19 pandemic and during a shortage of immediate-release mixed amphetamine salts in October ...

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.

Decrease in use seen among older adults, adults with low ASCVD risk, but also among those with higher ASCVD risk ...

(HealthDay News) — There is considerable uncertainty regarding the effects of puberty blockers in young individuals experiencing gender dysphoria (GD), according to two reviews published online Jan.

The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.